🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
At present, there is no standard second-line treatment of refractory and re...
Status
Unknown
Location
he First Affiliated Hospital of Guangzhou Medical College
Start Date
2012-10
Trial ID
NCT01872416
Treatments Being Tested
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor grow...
Status
Unknown
Location
Memorial Sloan-Kettering Cancer Center
Start Date
2006-07
Trial ID
NCT00436709
The main objective of the trial is to document the progression free surviva...
Status
Completed
Location
Istituto Clinico Humanitas
Start Date
2007-02-14
Trial ID
NCT00483509
Treatments Being Tested
The purpose of this study is to determine efficacy of treatment with bortez...
Status
Completed
Location
Multiple Locations
Start Date
2009-01
Trial ID
NCT00872521
Treatments Being Tested
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cell...
Status
Completed
Location
Lund University Hospital
Start Date
1996-04
Trial ID
NCT00002764
Treatments Being Tested
The purpose of this study is to evaluate time to progression, overall survi...
Status
Completed
Location
Multiple Locations
Start Date
2004-12
Trial ID
NCT00103506
Treatments Being Tested
This clinical trial is evaluating tucatinib in combination with Doxil in pa...
Status
Recruiting
Location
Maryland Oncology Hematology
Start Date
2023-07-24
Trial ID
NCT05748834
The purpose of this study is to evaluate the safety and efficacy of pembrol...
Status
Completed
Location
St Joseph Heritage Healthcare-Oncology ( Site 0004)
Start Date
2021-10-07
Trial ID
NCT05008224
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (...
Status
Active Not Recruiting
Location
The University of Arizona Cancer Center - North Campus /ID# 242219
Start Date
2022-06-14
Trial ID
NCT05283720
Apatinib mesylate is a multitarget receptor tyrosine kinase inhibitor. This...
Status
Unknown
Location
Sun Yat-sen University Cancer Center
Start Date
2019-08-20
Trial ID
NCT04012827
Treatments Being Tested